A Historical Perspective on First-Line Treatment of NSCLC and Recent Advances in Immunotherapy

In the first article of this series, Moshe Ornstein, MD, a genitourinary medical oncologist at the Cleveland Clinic, gives an overview of renal cell carcinoma and discusses the treatment landscape.

In the third interview of this series, Edward B. Garon, MD, reviews the treatment landscape in non–small cell lung cancer, with a focus on immunotherapy and the recent approval of tremelimumab in combination with durvalumab and platinum-based chemotherapy.

Brian Hill, MD, discusses the use of CAR T-cell therapy in earlier lines of treatment for mantle cell lymphoma and identifies other novel agents in this setting.

In an interview with Targeted Oncology, Everett E. Vokes, MD, discussed precision oncology for head and neck cancer and how the molecular biology of head and neck cancers is an opportunity for new investigations and treatment development.

Manmeet Ahluwalia, MD, discusses the purpose behind the Inaugural Miami Cancer Institute Precision Oncology Symposium.

Edward B. Garon, MD, Professor of Medicine, and Director of the Thoracic Oncology group at the David Geffen School of Medicine at UCLA, reviews key clinical trial data and explains the rationale of using combination IO therapies in the treatment of non-small cell lung cancer (NSCLC).